HCPLive

Emergency Care Providers Have Poor Hand Hygiene

THURSDAY, Nov. 14 (HealthDay News) -- Only 13 percent of emergency medical personnel say they clean their hands before touching patients, according to the results of a survey presented at the annual meeting of the American College of Emergency Physicians, held from Oct. 14 to 17 in Seattle.

Josh Bucher, MD, from the Robert Wood Johnson Hospital in Piscataway, NJ, and colleagues surveyed nearly 1,500 emergency care providers regarding their demographics and hand washing practices.

The researchers found that only 52 percent of the respondents -- which included first responders, emergency medical providers, paramedics, and doctors -- said that they wear gloves for every patient contact. Only 33 percent of emergency medical providers said they cleaned their hands after performing invasive procedures, and only 13 percent said they clean their hands before touching patients. In addition, only 13 percent of respondents said they cleaned their stethoscope between patients.

"In one of the largest studies of emergency medical services [EMS] provider hand hygiene to date, this study found several areas of EMS provider hand hygiene that are less than ideal," the authors write. "These are all very troubling findings, and they all identify areas where further education can provide direct results and increase hygiene compliance in these critical situations."

Abstract (subscription or payment may be required)
More Information

Copyright © 2013 HealthDay. All rights reserved.

Most Popular

Recommended Reading

Tenofovir alafenamide, which results in 90% lower circulating plasma tenofovir than standard tenofovir disoproxil fumarate, is associated with similar virologic response rates as the standard regimen, but with an improved safety profile.
Combination treatment with daclatasvir and asunaprevir plus interferon/ribavirin had high success rates in a 24-week clinical trial for treatment of hepatitis C in patients coninfected with HIV.
An interferon/ribavirin-free pill that combines two drugs to treat patients with certain genotypes of hepatitis C who are also infected with HIV was found to be highly effective in a 12-week trial, clearing the hepatitis C virus from almost all the patients involved.
Novel second-generation HIV-1 maturation inhibitor shows favorable antiviral activity and safety profile in HIV-1, subtype B-infected subjects
$vAR$